Procter & Gamble Health
- Advice
- Hold
Procter & Gamble Health Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Procter & Gamble Health
Start SIPProcter & Gamble Health Investment Rating
-
Master Rating:
-
Procter & Gamble Health has an operating revenue of Rs. 1,139.16 Cr. on a trailing 12-month basis. An annual revenue growth of 10% is good, Pre-tax margin of 23% is great, ROE of 31% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 53 which is a POOR score indicating inconsistency in earnings, a RS Rating of 37 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D+ which indicates heavy supply, Group Rank of 99 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|
| Oper Rev Qtr Cr | 298 | 296 | 268 |
| Operating Expenses Qtr Cr | 207 | 236 | 199 |
| Operating Profit Qtr Cr | 91 | 59 | 69 |
| Depreciation Qtr Cr | 7 | 7 | 6 |
| Interest Qtr Cr | 0 | 0 | 0 |
| Tax Qtr Cr | 23 | 13 | 14 |
| Net Profit Qtr Cr | 64 | 41 | 51 |
Procter & Gamble Health Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 7
- Bearish Moving Average
- ___
- 9
- 20 Day
- 4068.41
- 50 Day
- 4096.89
- 100 Day
- 4144.62
- 200 Day
- 4292.02
- 20 Day
- 4048.74
- 50 Day
- 4101.89
- 100 Day
- 4132.28
- 200 Day
- 4211.63
Procter & Gamble Health Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 4076.1 |
| Second Resistance | 4102.05 |
| Third Resistance | 4120.11 |
| RSI | 45.09 |
| MFI | 49.63 |
| MACD Single Line | -12.7 |
| MACD | -10.36 |
| Support | |
|---|---|
| First Resistance | 4032.1 |
| Second Resistance | 4014.05 |
| Third Resistance | 3988.1 |
Procter & Gamble Health Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 4,557 | 276,792 | 60.74 |
| Week | 4,434 | 243,618 | 54.94 |
| 1 Month | 9,001 | 526,131 | 58.45 |
| 6 Month | 8,853 | 604,834 | 68.32 |
Procter & Gamble Health Result Highlights
Procter & Gamble Health Synopsis
NSE-Medical-Generic Drugs
P&G Health is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 1114.41 Cr. and Equity Capital is Rs. 16.60 Cr. for the Year ended 30/06/2022. Procter & Gamble Health Ltd. is a Public Limited Listed company incorporated on 26/04/1967 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L99999MH1967PLC013726 and registration number is 013726.| Market Cap | 6,711 |
| Sales | 1,139 |
| Shares in Float | 0.80 |
| No of funds | 121 |
| Yield | 1.3 |
| Book Value | 10.89 |
| U/D Vol ratio | 0.6 |
| LTDebt / Equity | |
| Alpha | -0.08 |
| Beta | 0.44 |
Procter & Gamble Health
| Owner Name | Dec-22 | Sep-22 | Jun-22 | Mar-22 |
|---|---|---|---|---|
| Promoters | 51.82% | 51.82% | 51.82% | |
| Mutual Funds | 7.28% | 6.9% | 6.61% | |
| Insurance Companies | 5.11% | 5.66% | 1.46% | |
| Foreign Portfolio Investors | 6.33% | 6.05% | 6.47% | |
| Financial Institutions/ Banks | ||||
| Individual Investors | 24.32% | 24.46% | 25.09% | |
| Others | 5.14% | 5.11% | 8.55% |
Procter & Gamble Health Management
| Name | Designation |
|---|---|
| Mr. Suresh Talwar | Chairman & Ind.Director |
| Mr. Milind Thatte | Managing Director |
| Mr. Amit Gupta | Executive Director & CFO |
| Mr. Aalok Agrawal | Non Executive Director |
| Dr. Elizabeth Desmond | Non Executive Director |
| Mrs. Rani Jadhav | Independent Director |
| Mr. S Madhavan | Independent Director |
Procter & Gamble Health Forecast
Price Estimates
Procter & Gamble Health Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2023-02-05 | Quarterly Results & Interim Dividend | |
| 2022-11-11 | Quarterly Results | (Revised) per share(150%)Dividend |
| 2022-08-29 | Audited Results & Final Dividend | |
| 2022-05-05 | Quarterly Results & Interim Dividend | |
| 2022-02-09 | Quarterly Results |
| Date | Purpose | Remarks |
|---|---|---|
| 2023-02-13 | INTERIM | Interim Dividend |
| 2022-05-13 | INTERIM | Rs.41.00 per share(410%)Interim Dividend |
Procter & Gamble Health FAQs
What is Share Price of Procter & Gamble Health ?
Procter & Gamble Health share price is ₹4070 As on 30 January, 2023 | 04:24
What is the Market Cap of Procter & Gamble Health ?
The Market Cap of Procter & Gamble Health is ₹6756 Cr As on 30 January, 2023 | 04:24
What is the P/E ratio of Procter & Gamble Health ?
The P/E ratio of Procter & Gamble Health is 33.6 As on 30 January, 2023 | 04:24
What is the PB ratio of Procter & Gamble Health ?
The PB ratio of Procter & Gamble Health is 11 As on 30 January, 2023 | 04:24